Avinger, Inc. (AVGR)
Chart Events
Performance Outlook
| Previous Close | 1.3600 |
| Open | 1.3700 |
| Bid | 1.2900 x 800 |
| Ask | 1.3000 x 1000 |
| Day's Range | 1.2800 - 1.3700 |
| 52 Week Range | 0.2140 - 2.6700 |
| Volume | 835,515 |
| Avg. Volume | 14,064,411 |
| Market Cap | 124.364M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4650 |
| Earnings Date | Mar 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
Fair Value
Related Research
- ACCESSWIRE
Avinger Provides Update on Tigereye(TM) Commercial Launch
REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the commercial launch of Tigereye CTO Crossing catheters for the treatment of PAD.
- Benzinga
Avinger: Q4 Earnings Insights
Avinger (NASDAQ:AVGR) reported Q4 results on Thursday afternoon. Quarterly Results Earnings per share were up 87.93% over the past year to ($0.07), which missed the estimate of ($0.06). Revenue of $2,732,000 rose by 6.64% from the same period last year, which beat the estimate of $2,450,000. Outlook Avinger hasn't issued any earnings guidance for the time being. Avinger hasn't issued any revenue guidance for the time being. Conference Call Details Date: Mar 11, 2021 View more earnings on AVGR Time: 04:30 PM ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2212/40203 Recent Stock Performance Company's 52-week high was at $2.67 Company's 52-week low was at $0.21 Price action over last quarter: Up 569.20% Company Description Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 11, 2021Earnings Outlook For Avinger© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- ACCESSWIRE
Avinger Reports Fourth Quarter 2020 Financial Results
19% Sequential Increase in Total RevenueTigereye™ Drives 38% Sequential Growth in Image-Guided CTO RevenueREDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the fourth quarter ended December 31, 2020.
